Dianthus | Affinity Screening

  • Get fast, non-stop, highly sensitive hit screening with Dianthus.2:55

    Get fast, non-stop, highly sensitive hit screening with Dianthus.

    Dianthus removes the complexity of binding interaction measurements for drug discovery screening. Find hits for any target type in any buffer or bioliquid, measure the tightest interactions down to pi

    Watch
  • Because you demand fast, non-stop, highly sensitive hit screening.

    Because you demand fast, non-stop, highly sensitive hit screening.

    Read
  • How to find promising small molecule lead compounds with biophysical tools25:01

    How to find promising small molecule lead compounds with biophysical tools

    Watch this webinar if you’re working in the field of small molecule drug discovery and want to learn how scientists in this field use biophysical tools to search for the most promising lead compounds.

    Watch
  • Ready to tackle your challenging affinity screening?

    Discover tools you can use

    Learn more
  • Going small to win big: Fragment-based screening in drug discovery

    Going small to win big: Fragment-based screening in drug discovery

    Read
  • Targeted protein degradation promises to lead the way to effective drugs for challenging targets

    Targeted protein degradation promises to lead the way to effective drugs for challenging targets

    Read
  • High-throughput determination of protein affinities using unmodified peptide libraries in nanomolar scale

    High-throughput determination of protein affinities using unmodified peptide libraries in nanomolar scale

    Read
  • Why so many companies are betting on PROTACs as a superior therapeutic modality

    Why so many companies are betting on PROTACs as a superior therapeutic modality

    With PROTACs currently in the clinical and preclinical stages, they are making exciting progress towards successfully treating patients who have been waiting for effective therapies for certain...

    Read
  • Improve your protein degrader design with new ways to discover E3 ligase ligands35:47

    Improve your protein degrader design with new ways to discover E3 ligase ligands

    Targeted protein degradation using molecular glues or proteolysis-targeting chimeras (PROTACs) is an increasingly important therapeutic modality, especially for undruggable targets. Even with candidat

    Watch
  • MST and TRIC technology to reliably study PROTAC binary and ternary binding in drug development

    MST and TRIC technology to reliably study PROTAC binary and ternary binding in drug development

    Read
  • Fast Mek1 hit identification with TRIC technology correlates well with other biophysical methods

    Fast Mek1 hit identification with TRIC technology correlates well with other biophysical methods

    Read
  • Adventures in drug discovery - The quest for your best small molecule56:52

    Adventures in drug discovery - The quest for your best small molecule

    Are you working in the field of small molecule drug discovery? Join this webinar to explore the drug discovery workflow and discover tools that can help in your quest for the most promising lead com

    Watch
  • Understanding the nuances of targeted protein degradation59:35

    Understanding the nuances of targeted protein degradation

    Bifunctional degrader molecules (also known as PROTACs) and molecular glues recruit proteins to E3 ubiquitin ligases. The formation of a ternary complex between PROTAC, ligase, and the protein of inte

    Watch
  • Tackle undruggable targets by screening for binary and ternary PROTAC interactions using Dianthus

    Tackle undruggable targets by screening for binary and ternary PROTAC interactions using Dianthus

    Read
  • Are you building an effective protein degrader?

    Are you building an effective protein degrader?

    Read
  • Protein degraders show promising results in drug development pipelines. See progress candidates have made.

    Protein degraders show promising results in drug development pipelines. See progress candidates have made.

    There has been considerable and promising development in the field of targeted protein degradation (TPD) since the seminal discovery of PROTACs in 2001.1 The appeal of degraders like PROTACs lies...

    Read
  • Is your screening campaign stuck? 3 signs that it’s time to look for an alternative biophysical technology

    Is your screening campaign stuck? 3 signs that it’s time to look for an alternative biophysical technology

    Most labs dedicated to drug discovery — in big pharma, biopharma, or CROs — make it a priority to have an adequate lineup of instruments for their screening campaigns. They decide on what...

    Read
  • Follow these 7 tips when pipetting small volumes to get consistent assay results

    Follow these 7 tips when pipetting small volumes to get consistent assay results

    If you’ve ever had to pipette really small volumes, such as what is required in 384-well plates, you’re definitely familiar with the frustrations that come along with it. The concentration alone...

    Read
  • 4 ways to help you overcome the limitations of current methods in neurodegenerative disease research

    4 ways to help you overcome the limitations of current methods in neurodegenerative disease research

    Read
  • 6  protein degradation conferences in 2021 you can’t afford to miss

    6 protein degradation conferences in 2021 you can’t afford to miss

    Conferences in 2021 will gather scientists and experts eager to discuss new discoveries in the emerging field of targeted protein degradation (TPD). Many transcription factors, scaffold proteins,...

    Read
  • 3 case studies on how to characterize challenging drug discovery targets — membrane proteins, peptide libraries, and PROTACs

    3 case studies on how to characterize challenging drug discovery targets — membrane proteins, peptide libraries, and PROTACs

    A caveat to a successful pharmaceutical industry in which many effective drugs have already been discovered is the notion that the high hanging fruits left unpicked come in the form of challenging...

    Read
  • loading
    Loading more...